logo
  

Henry Schein Acquires 70% Of EAssist Dental Solutions For Undisclosed Terms - Quick Facts

Healthcare solutions company Henry Schein, Inc. (HSIC) announced Tuesday that it has acquired a 70% ownership position in eAssist Dental Solutions, the developer of a leading and fast-growing virtual dental billing outsourcing service. Financial terms were not disclosed.

eAssist will help advance Henry Schein's mission to offer best-of-breed solutions to help dental practices operate more efficiently and profitably, freeing up practice resources to focus on patient care.

eAssist was founded in 2011 by James Anderson, DMD, and Sandy Odle to assist with billing challenges in his dental practices. Anderson will continue to manage the eAssist business as Chief Executive Officer, along with the current eAssist management team.

Henry Schein expects that eAssist will be slightly dilutive to the Company's 2021 financial results and to be accretive thereafter. Financial terms were not disclosed.

eAssist is currently designed to support dental practices of all sizes through technology supported by a network of dental billing professionals. In addition to its core dental billing service, newer offerings from eAssist include securing detailed patient eligibility information, billing certain dental procedures through medical insurance, and practice bookkeeping.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT